This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Clinical trials are expensive, slow and often limited by outdated design constraints. These digital twins are created for each trial participant using their baseline data – regardless of whether they are assigned to the placebo or treatment arm – and simulate how that individual would have responded under control conditions.
Clinical trials have changed, and so have the expectations placed on the teams that run them. Trials move faster, are more fragmented, generate more data, and are under growing pressure to deliver real-time insights with audit-ready precision and regulatory oversight.
The journey of cell and gene therapies from preclinical discovery to clinical trials is complex and challenging, impacting every team member involved, from researchers in the lab to patients receiving treatment. These digital platforms are designed to manage and automate critical trial processes, especially related to drug management.
From advancing drug discovery, managing clinical trials, or developing new healthcare solutions, reliable and flexible access to quality data is essential for success. From early-stage drug discovery to complex clinical trials, Snowflake scales alongside your work to meet your growing demands.
Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating salanersen (BIIB115/ION306) , an investigational antisense oligonucleotide (ASO) therapy for spinal muscular atrophy (SMA).
Types of Drug Applications The PMDA accepts three main types of drug applications: Investigational New Drug (IND) : Required for conducting clinical trials in Japan. Challenges and Opportunities Ethnic Bridging : Japan has historically required clinical trials to be conducted within the country to account for ethnic differences.
A surrogate endpoint is a marker used in clinical trials as a substitute for a direct clinical outcome. Diagnostic biomarkers typically confirm or establish a diagnosis and are often used in selecting patient populations for clinical trials.
From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape. Drug development The rising cost of clinical trials is the top challenge this year, due to increasingly complex protocol designs and difficult patient recruitment.
Cost and complexity go hand-in-hand The rising costs and growing complexity in clinical trials are deeply linked, with patient recruitment, extended timelines and meeting regulatory demands emerging as some of the key drivers. Nearly half (49%) of clinical trial sponsors surveyed identified rising costs as their foremost concern in 2024.
It involves a dynamic and often unpredictable process where every stage, from target identification to clinical trials, generates vast amounts of data. Additionally, AI-driven predictive modelling can shorten the preclinical phase by simulating biological responses, leading to more targeted and efficient clinical trials. The result?
Regulatory Risks of Wearables in Clinical Trials Are Real (and Avoidable) Wearables have become indispensable in modern clinical trials, tracking. The post Ensuring Regulatory Compliance When Using Wearables in Clinical Trials appeared first on Crucial Data Solutions.
“Protocol development can be a complex and meticulous process,” he explains, “as it’s crucial to ensure that trial candidates meet the necessary inclusion criteria.” Prior treatments and patient histories often introduce variables that can affect outcomes, making thoughtful trial design essential for generating reliable data.
Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period. Drugs that require extensive clinical trials for generic approval or fall under special regulatory pathways may have a lower risk of generic entry.
From retinal repair to diabetes treatment, induced pluripotent stem cell (iPSC)-derived cell therapies are entering clinical trials with increasing numbers over the last few years since their first generation and characterization 18 years ago.
Such an approach ensures reliable preclinical toxicology data and supports the transition of innovative therapies from the lab to clinical trials. An approach grounded in GLP, coupled with advanced analytical techniques, is essential for effectively mitigating matrix effects.
The landscape of Indian clinical trial regulations has undergone a profound transformation over the past two decades. Once perceived as a regulatory gray zone, the Indian clinical research ecosystem has […] The post A Closer Look at Compliance and Regulations for Drug Clinical Trials in India appeared first on ProRelix Research.
The European Commission’s approval is based on robust data from the FELIX Phase 1b/2 trial, which demonstrated compelling efficacy and a favorable safety profile in adult patients. These clinical findings contributed not only to the FDA’s decision in 2024 but also to accelerating the product’s path to market across Europe.
Emprove® Program – Designed to support regulatory compliance and quality assurance, the Emprove® framework provides detailed documentation for raw materials, process chemicals, and single-use products, making regulatory filings more efficient and transparent.
Errors jeopardize patient safety, regulatory compliance and trust. In clinical trials, generative AI accelerates trial designs through protocol optimization and enrollment forecasting, leading to faster and more effective studies. This maintains regulatory compliance and patient safety. But the stakes are uniquely high.
In an era where clinical trials are increasingly global, it’s more imperative than ever to leverage international expertise. Data and safety monitoring boards (DSMBs), also known as data monitoring committees (DMCs), play a critical role in overseeing a clinical trial’s safety and efficacy.
Designed to better manage risk, patient safety, and data integrity in clinical trials, the updated guideline is expected to be adopted by regulatory authorities worldwide. As such, research organizations must critically evaluate both their clinical priorities and operational procedures to ensure compliance.
Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials. NHP-C cardiomyocytes offer a more predictive and ethical platform, especially for drugs intended to advance from animal testing to first-in-human trials.
Whether you’re at the discovery phase or gearing up for a clinical trial , your first conversation with a CRO is an excellent opportunity to assess the cultural fit and collaborative potential. Let the CRO know any key outcomes from each.
The guidance ensures that these targeted evaluations help identify and mitigate safety concerns early in the development process, supporting the safe progression of oligonucleotide therapies into clinical trials. Our experts stay up to date on all new and evolving regulations to guarantee regulatory compliance in your studies.
By the time of NDA submission, a sponsor should be able to demonstrate that the clinical materials used in pivotal trials are representative of the proposed commercial processes and product. Compliance with good manufacturing practices (GMP). Batch testing. This is the final step in ensuring product consistency and quality.
The failure rate in clinical trials exceeds 90%, often due to insufficient safety data, efficacy concerns, or regulatory non-compliance. Even drugs that complete clinical trials may face delays or rejections if submission documents are incomplete or do not align with regulatory expectations.
The new phase focuses on turning these previously isolated technology transfer initiatives into a sustainable, commercial enterprise — a network of fully GMP-compliance facilities that can produce mRNA vaccines and therapeutics at scale. Today, the Programme stands at a turning point, as it moves into its Phase 2.0 2026–2030).
For example, AI tools can pull data from protocols and automatically update clinical trial management systems (CTMS), reducing manual entry errors and increasing workflow speed. This same data could be used to auto-generate study calendars based on the schedule of assessments, streamlining trial planning.
The RedirecTT-1 trial shows the power of this novel combination approach as a potential treatment option for these patients, many of whom have limited options after multiple lines of therapy.” Patients were able to switch to once a month dosing , which may contribute to improved tolerability and patient compliance.
Are you in early-stage clinical trials, or are you gearing up for commercial launch? Managing Quality and Compliance Quality and regulatory compliance are non-negotiable in pharmaceutical manufacturing. Navigating Regulatory Challenges Regulatory compliance is a complex area, especially for startups.
This report provides a comprehensive breakdown of clinical trial costs by phase and therapeutic area, with a focus on key cost components including per-patient costs, total costs, CRO fees, and […] The post Phase-by-Phase Clinical Trial Costs: What Every Sponsor Needs to Know! appeared first on ProRelix Research.
However, recent advancements and strategic approaches in clinical trials offer hope that additional treatments are on the way. Several clinical trials have progressed to Phase III and, if successful, have the potential to alter the standard of care. That’s why minimizing patient burden is critical to IPF trial success.
In the past decade alone, the time needed to complete a clinical trial has increased by 20–30%, and the cost to bring a new drug to market has risen to an average of about $2.6 Biopharmaceutical and biotech drug developers have faced increasing challenges in recent years.
Its also critical that the solution aligns with regulatory standards for RWD use, ensuring confidence and compliance from the start. You can unsubscribe at anytime. A data-agnostic GenAI tool ensures flexibility and usability, helping teams create tailored patient profiles without deep technical expertise. inhibitors. inhibitors.
The company continues to invest heavily in integrated manufacturing capabilities that ensure quality, scalability, and compliance with global regulatory standards. In parallel with its technological advances, JCR has made significant strides in global research and development infrastructure.
“A big part of my role involves interacting with customers, learning from them on their challenges and providing solutions to expedite their path to clinical trials or commercialisation of their drug,” Galbraith explains. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.
When these trials fail, the repercussions can be devastating, leading to layoffs and a significant loss of morale among remaining team members. One of the biggest contributors to these unsustainable costs is companies building extensive in-house infrastructures based on antiquated assumptions about drug development.
This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. The SELECT trial set out to understand whether the drug has similar effect on patients without diabetes. As of mid-2024, this includes at least 650 Phase I-IV trials, with about 430 of those already ongoing.
From instrument integration to data processing, automation ensures regulatory compliance and enhanced scalability, which is necessary for the increasing demand for novel treatments across therapeutic areas. Biomarkers support adaptive trial designs, allowing modifications based on interim results to optimize study outcomes.
ADA Compliance Overview ADA compliance ensures websites are accessible to people with disabilities, promoting inclusivity and fairness. The tool offers a 30-day free trial, a downloadable version,and a web-based option for scanning websites and pages for accessibility testing. By following the WCAG 2.0
For more than 35 years, Advarra has been committed to protecting the rights and welfare of clinical trial participants while helping to improve healthcare outcomes, advancing medical knowledge, and bringing innovative, life-extending treatments to market that benefit millions of patients worldwide.
.” Addressing Unique Challenges in Digital Transformation Life sciences organizations face several challenges in digital transformation, including legacy systems, siloed data, regulatory compliance, and clinical trial modernization. Future Advancements and Innovations The power of Life Sciences Cloud is just beginning.
In contrast, an adaptive trial design allows for modifications to an ongoing trial and its analyses under a pre-specified framework, which is outlined in the FDAs Adaptive Designs for Clinical Trials for Drugs and Biologics Guidance for Industry, published in 2019.
In our latest blog post, we delve into the compliance hurdles that generic drug developers face, and the valuable lessons learned from these experiences. From navigating complex regulatory landscapes to ensuring the integrity of clinical trials, the stakes are high for generic drug manufacturers. Read the full article here: [link]
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content